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The incidence of PPCM shows large temporal and geographic variations, with more recent articles suggesting an incidence of 1 in Ϸ2000 to 4000 deliveries (ie, affecting 1000 to 2000 women annually in the United States). 1, 8 Even higher rates have been reported from South Africa (1:1000), Haiti (1:300), and Nigeria (1:100). 1, 3 Some of these differences may be accounted for by diagnostic criteria (eg, clinical only versus echocardiographic) and others by pathogenic factors (eg, dietary salt, hypertension, genetic background). 3 The clinical presentation of PPCM is indistinguishable from IDCM (ie, new appearance of clinical signs and symptoms of heart failure due to systolic dysfunction, such as fatigue, dyspnea, pulmonary and peripheral edema, and thromboembolic risk). 1, 3 Treatment goals also are generally similar to that of heart failure of other pathogeneses, that is, to relieve congestive symptoms (diuretics), optimize hemodynamics (afterload reduction), and improve short-and longterm prognosis (eg, beta-blockers). However, special attention must be given to safety (ie, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers should be avoided during pregnancy and early postpartum nursing).
PPCM is a leading cause of pregnancy-related morbidity and mortality. [1] [2] 9 It represents the leading cause of pregnancy-related death, although mortality, once reported to be as high as 50%, may be significantly reduced by early recognition and treatment. [1] [2] [3] 10 Although the potential for reversibility of PPCM-related heart failure is widely recognized, more than half of patients do not recover normal or near-normal function within 6 months. 1-3,10 -11 The impact of the loss or incapacity of a mother of an infant, and often of other young children, goes well beyond these statistics alone.
Several common risk factors for PPCM have been identified, but a common underlying pathogenesis remains obscure. 11 These risk factors include age Ͼ30, multiparity, multiple gestations, preeclampsia and eclampsia, and prolonged tocolytic therapy with beta-agonists. [1] [2] [3] 11 African descent as a risk factor is controversial. Proposed hypotheses to explain pathogenesis include hemodynamic factors (eg, increased cardiac demand of pregnancy, hypertension), dietary deficiencies (eg, selenium) or excesses (eg, salt), a pathological maternal immune response (eg, to fetal antigens), myocarditis (viral or antigen induced), hormonal abnormalities, and oxidative stresses, including pregnancyassociated increases in inflammatory cytokines (eg, tumor necrosis factor-␣, interleukin-6, C-reactive protein) and apoptosis-signaling pathways (eg, cathepsin D , Fas/Apo-1). 1, 3, [11] [12] Activation of signaling pathways (eg, c-SRc-Akt and signal transducer and activator of transcription 3) normally protects the maternal heart from these oxidative stresses. 1, 3, 13 Uncompensated oxidative stress mediated by cleavage of the nursing hormone prolactin into an antiangiogenic and proapoptotic 16-kDa form recently has been proposed to be a specific pathogenic mechanism of PPCM, and blockade of prolactin cleavage with bromocriptine has shown therapeutic promise. [13] [14] Some articles 15 but not others 2,6 have noted familial clustering in PPCM. 16 However, a genetic basis for PPCM has not been systematically studied. IDCM, the phenotypic mimic of PPCM, is now thought to be familial (Familial Dilated Cardiomyopathy [FDC]) in 20% to 50% of cases. 17 This observation raises the possibility that underlying genetic variants common to dilated cardiomyopathy (DCM) may represent susceptibility factors for PPCM. In this issue of Circulation, two studies test the hypothesis that a proportion of cases of PPCM/PACM may be part of the spectrum of IDCM/FDC and that genetic mutations associated with DCM may contribute to its pathogenesis. 16, 18 Morales et al undertook a database study of the FDC Research Project, which enrolled subjects with familial and nonfamilial DCM and was designed for family-based and genetic studies. 17 women from 520 pedigrees, from which a review of clinical information revealed a diagnosis of PPCM/PACM in 45 cases. 18 Evidence of familial clustering of DCM was noted in 23 (55%) of the 42 unrelated cases. Genetic data were available from previous sequencing studies in 19 of these unrelated cases, 13 of which were familial and 6 sporadic. Most (nϭ14) had been comprehensively resequenced for all coding exons and intron/exon boundaries for 14 DCM genes; the others (nϭ5) had more limited sequencing information (ie, 1 to 12 genes). Six (32%) of these 19 cases (5 with PPCM and 1 with early PACM) were found to carry nonsynonymous mutations, each in a different gene. In the 4 with evidence of familial inheritance, mutations were found in MYH7, SCN5A, PSEN2, and (in the early PACM case) MYBPC3. In the 2 with sporadic disease, mutations were found in MYH6 and TNNT2.
Evidence for a pathogenic role varied, including absence of the mutation in 246 to 413 control subjects (for all 6 mutations), familial segregation with DCM (in 3), association with DCM in a prior article (in 1), and functional study articles (in 3). In a complementary article, van Spaendonck-Zwarts et al reviewed the FDC database of the University Medical Centre Groningen's cardiogenetics clinic and found 5 (6%) of 90 families with patients with PPCM. 16 In 1 of these families, PPCM occurred in 2 members. In a reverse approach, 10 independent cases of PPCM were identified in the database; screening of first-degree relatives of 3 cases with persistent DCM was then performed and showed undiagnosed DCM in all 3 families. Genetic analysis for 3 DCM genes in the 5 FDC families with PPCM was unrevealing, but more extensive analysis (10 genes) in 1 of these families identified a nonsynonymous mutation in TNNC1 not present in 300 control alleles and believed to be pathogenic based on cosegregation with disease and structural prediction algorithms.
Morales et al 18 and van Spaendonck-Zwarts et al 16 are to be congratulated on what may be viewed as the birthing of PPCM genetics: their studies represent the first systematic approaches to examining the familiality and genetics of PPCM/PACM cases as part of the spectrum of IDCM/FDC. Their results support the hypothesis that PPCM/PACM may develop as a result of a complex interaction of pregnancyassociated factors (eg, late-pregnancy associated oxidative stress 1,12-14 ) against a susceptible genetic background (ie, that peripartum oxidative stress causes a genetically susceptible woman to cross a threshold into clinical PPCM). 16 For the moment, these studies have few implications for clinical application, but they have important implications for the genetic hypothesis of PPCM.
Previous articles have been at variance on the question of familiality of PPCM, with mostly anecdotal cases in support, [15] [16] but two key studies did not report positive family histories as part of the PPCM profile. 2, 6 As noted by van Spaendonck-Zwarts et al, 16 the European Society of Cardiology currently classifies PPCM as a nonfamilial, nongenetic form of DCM. Morales et al 18 propose two explanations for reports of nonfamiliality: 1) differing pathogeneses for PPCM, and 2) (perhaps more likely) incomplete family history assessment. This group previously has shown the necessity for a careful, prospective, focused 3-to 4-generation history to detect FDC. 17, 19 Further, these 2 studies demonstrate that clinical screening of closely related family members adds additional sensitivity to detect FDC. 16, 18 Morales et al recommend that these 2 steps (3-to 4-generation family history, consideration of clinical screening for first-degree relatives) be added to all ongoing PPCM study designs. 18 The Dutch investigators showed that family letters are an effective way to inform relatives about inherited cardiac disease and encourage them to undergo screening. 20 Conceptually, the results of these studies are stimulating and open up new insights into potential genetic mechanisms of PPCM. Yet as these authors note, there are important limitations that deserve further emphasis. The studies are retrospective in nature and are limited to available clinical and genetic information. In the Morales study, adequate, although incomplete, information was available for only 19 of 45 PPCM/PACM cases. Evidence for proof of causation varied, with 2 variants (MYH7 and MYH6) having no functional or segregation data. In support, they note that MYH7 encodes the key sarcomeric beta-myosin heavy chain protein containing other mutations associated with DCM, and the MYH6 gene encodes alpha-myosin heavy chain, another sarcomeric protein with variants reported in DCM but with a less established role. 18 The van Spaendonck-Zwarts study makes a strong case for familiality but presents limited genetic evidence: only a single genetic variant in a single family was discovered.
The studies also are too limited to estimate how representative their cases and associated mutations are for PPCM in the general population. However, the cases meet the usual criteria for PPCM and so establish that genetic causation underlies some (albeit an uncertain) proportion of cases. Further, the data suggest that PPCM/PACM genetics is diverse, as with DCM, with mutations in neither a single gene nor a small cluster of genes dominating pathogenesis.
A final important limitation is that only a small part of the contribution of genetics to PPCM is explained. Further, even in families with defined mutations, extremely variable disease expression often was noted. 16, 18 Thus many pathogenic and modifier genes remain to be discovered, including those unrelated to IDCM/FDC. Indeed, PPCM has several unique distinguishing features, including activation by specific pregnancy-related clinical and biological factors. For cases in which IDCM/FDC genetics underlies PPCM, pregnancyrelated factors may trigger quiescent disease susceptibility into active PPCM. In other cases, variants in different genes, singly or in combination, may underlie disease activation. To simultaneously account for multiple genetic inputs, the concept of aggregate genetic risk score modeling is emerging. 21 Identification of PPCM-genetic variants currently may be addressed best by combining a candidate gene approach (as in these studies) with genome-wide association studies using high-density arrays ("chips"). 22 Contemporary genome-wide association studies technology can simultaneously assess from 500 ,000 to 1 million common variants, make no a priori assumptions about genomic site, and provide broad, genomewide coverage. The possibility of additional genetic discoveries for PPCM using genome-wide association studies has been suggested recently by a preliminary article from our Intermountain Heart Collaborative Study 23 : comparing a genome-wide significant association in 41 PPCM cases and 49 age-discordant controls, a genome-significant association was found for marker rs258415 on chromosome 12, with an odds ratio for the C allele of 6.0 (Pϭ2.1x10 -8 ) . Several other markers showed suggestive evidence. Efforts to validate and extend these findings are underway.
In conclusion, these promising findings for PPCM, although limited in number, clinical application, and conclusions, provide a strong incentive for cardiovascular investigators and funding agencies to invest in additional prospective studies of the genetics of this increasingly important disease. This effort should include large and prospective multicenter studies incorporating systematic screening of first-degree relatives and more extensive genetic screening. Future research holds great promise for additional genetic discovery in PPCM, which will be attended by new biological insights and may lead to improved disease risk assessment, prevention, prognosis, and therapy.
